A Phase 1/2, Multicenter, Open-label, Dose-confirmation Trial to Evaluate the Safety and Preliminary Efficacy of DYN101 in Participants 2 to 17 Years of Age With Centronuclear Myopathy Caused by Mutations in MTM1 or DNM2
Latest Information Update: 12 Jul 2022
Price :
$35 *
At a glance
- Drugs DYN-101 (Primary)
- Indications Congenital structural myopathies
- Focus Adverse reactions
- Acronyms DyNaMic
- Sponsors Dynacure
- 07 Jul 2022 Planned End Date changed from 1 Jun 2023 to 1 Nov 2025.
- 07 Jul 2022 Planned primary completion date changed from 1 Mar 2023 to 1 Sep 2025.
- 07 Jul 2022 Planned initiation date changed from 1 Oct 2021 to 1 Jan 2024.